FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million

Reuters

2025/11/11

FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million

FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582074978"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582074978\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582074978?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582074978","market":"fut","top_or_hot":-1,"title":"FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1zlJMR:1","article_id":"2582074978","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582074978","pubTimestamp":1762808552,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"FibroGen公布第三季度营收110万美元，净亏损1310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FGEN":0.9},"content_text":"FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million\n    \n\n        FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572632-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}